Plain-English translation of NCT07396155 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing allogeneic umbilical cord mesenchymal stem cell therapy as a new treatment for diabetic nephropathy—kidney damage caused by diabetes. Researchers will inject stem cells (which are young, flexible cells with healing potential) directly into your kidney and then monitor how well your kidneys function over the next year. The goal is to see whether this treatment can help reduce inflammation and slow the decline in kidney function that often happens in people with diabetes.
Standard diabetes and kidney treatments help many patients, but some people's kidneys continue to get worse despite taking medications. Scientists believe that inflammation plays a big role in kidney damage, and early research suggests that stem cells have anti-inflammatory and repair properties that might help protect kidney function—so this trial is testing whether that promise holds true in real patients.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of stem cells directly into your kidney during a procedure. After that, you'll visit the research clinic regularly over 12 months so doctors can check your kidney function, monitor your health, and watch for any side effects. Blood and urine tests will be done to track how your kidneys are responding to the treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Indonesia